1Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol, 2004, 41: 38-43.
2Als Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systemalic review of randomised trials. BMJ, 2004, 328:1046.
3Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther, 2007, 25 (Suppl. 1): 23-31.
4Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double blind, double dummy, controlled clinical trial. J Hepatol, 2003, 38:51-58.
5Leevy CB, Phillips JA. Hospitalizations during the use of Rifaximin versus lactulose for lhe Treatment of Hepatic Encephalopathy. Dig Dis Sci, 2007, 52:737-741.
6Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol, 2005, 3:184-191.
7Kircheis G, Wettstein M, Dahl S, et al. Clinical efficacy of L- ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis, 2002, 17: 453-462.
8Bianchi G, Marzocchi R, Agostini F, et al. Update on branched chain amino acid supplementation in liver diseases. Curr Opin Gastroenterol, 2005, 21: 197-200.
9Sehmidt LE, Tofteng F, Strauss GI, et al. Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy. Stand J Gastroenterol, 2004, 39: 974-980.
10Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology, 2001, 120:749-762.
